What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion

References

• Ermer JC, Pennick M, Frick G. Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy. Clin Drug Investig. 2016;36(5):341–356.
   Google Scholar
• Goodman DW. Lisdexamfetamine dimesylate (Vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. Pharm Ther. 2010;35:273–287.
   Google Scholar
• Siffel C, Page M, Maxwell T, et al. Patterns of lisdexamfetamine dimesylate use in children, adolescents, and adults with attention-deficit/hyperactivity disorder in Europe. J Child Adolesc Psychopharmacol. 2020;30(7):439–447.
   Google Scholar
• Food and Drug Administration. Vyvanse (lisdexamfetamine dimesylate) [Internet]. 2007. [cited March 2022 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021977lbl.pdf
   Google Scholar
• Coghill DR, Caballero B, Sorooshian S, et al. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs. 2014;28(6):497–511.
   Google Scholar
• Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317–327.
   Google Scholar
• Ward K, Citrome L. Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder. Expert Opin Drug Metab Toxicol. 2018;14(2):229–238.
   Google Scholar
• Strajhar P, Vizeli P, Patt M, et al. Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: a randomized, double-blind, placebo-controlled study. J Steroid Biochem Mol Biol. 2019;186:212–225.
   Google Scholar
• Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol Oxf Engl. 2009;23(4):410–418.
   Google Scholar
• Heal DJ, Buckley NW, Gosden J, et al. A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil. Neuropharmacology. 2013;73:348–358.
   Google Scholar
• Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol Oxf Engl. 2009;23(4):419–427.
   Google Scholar
• Ermer JC, Dennis K, Haffey MB, et al. Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. Clin Drug Investig. 2011;31(6):357–370.
   Google Scholar
• Heal DJ, Smith SL, Gosden J, et al. Amphetamine, past and present–a pharmacological and clinical perspective. J Psychopharmacol Oxf Engl. 2013;27(6):479–496.
   Google Scholar
• Dolder PC, Strajhar P, Vizeli P, et al. Pharmacokinetics and pharmacodynamics of lisdexamfetamine compared with D-amphetamine in healthy subjects. Front Pharmacol. 2017;8:617.
   Google Scholar
• Rowley HL, Kulkarni R, Gosden J, et al., Lisdexamfetamine and immediate release d-amfetamine – differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity. Neuropharmacology. 2012;63(6):1064–1074.
   Google Scholar
• Yun J, Lee K-W, Eom J-H, et al. Potential for dependence on lisdexamfetamine - in vivo and in vitro aspects. Biomol Ther. 2017;25(6):659–664.
   Google Scholar
• Banks ML, Hutsell BA, Blough BE, et al. Preclinical assessment of lisdexamfetamine as an agonist medication candidate for cocaine addiction: effects in rhesus monkeys trained to discriminate cocaine or to self-administer cocaine in a cocaine versus food choice procedure. Int J Neuropsychopharmacol. 2015;18:1–10.
   Google Scholar
• Krishnan S, Montcrief S. Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies. Basic Clin Pharmacol Toxicol. 2007;101(4):231–240.
   Google Scholar
• McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235–246.
   Google Scholar
• Gasior M, Hudson J, Quintero J, et al. A phase 3, multicenter, open-label, 12-month extension safety and tolerability trial of lisdexamfetamine dimesylate in adults with binge eating disorder. J Clin Psychopharmacol. 2017;37(3):315–322.
   Google Scholar
• McElroy SL, Martens BE, Mori N, et al. Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2015;30(1):6–13.
   Google Scholar
• Ezard N, Clifford B, Dunlop A, et al. Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study. BMJ Open. 2021;11(5):e044696.
   Google Scholar
• Cassidy TA, Varughese S, Russo L, et al. Nonmedical use and diversion of ADHD stimulants among U.S. adults ages 18-49: a national internet survey. J Atten Disord. 2015;19(7):630–640.
   Google Scholar
• Cassidy TA, McNaughton EC, Varughese S, et al. Nonmedical use of prescription ADHD stimulant medications among adults in a substance abuse treatment population: early findings from the NAVIPPRO surveillance system. J Atten Disord [Internet]. 2015 [cited 2022 Feb 7];19. Available from: https://pubmed.ncbi.nlm.nih.gov/23900405/
   Google Scholar
• Kaland ME, Klein-Schwartz W. Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers. Clinical Toxicology. 2015;53(5):477–485.
   Google Scholar
• Attention deficit hyperactivity disorder: diagnosis and management | guidance and guidelines | NICE [Internet]. [cited 2018 Jul 12]. Available from: https://www.nice.org.uk/guidance/ng87/chapter/Recommendations#medication
   Google Scholar
• Brownley KA, Berkman ND, Peat CM, et al. Binge-eating disorder in adults: a systematic review and meta-analysis. Ann Intern Med. 2016;165(6):409–420.
   Google Scholar
• Chappuy M, Boulanger A, Nourredine M, et al. Disparate regulatory status of methylphenidate for adults with ADHD across Europe. Lancet Psychiatry. 2020;7(1):e1–e2.
   Google Scholar
• Brams M, Weisler R, Findling RL, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73(7):977–983.
   Google Scholar
• Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364–1373.
   Google Scholar
• Wigal T, Brams M, Gasior M, et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct BBF. 2010;6(1):34.
   Google Scholar
• Lapeyre-Mestre M, Boucher A, Daveluy A, et al. Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapie. 2020;75(4):343–354.
   Google Scholar